From Wikipedia, the free encyclopedia
Chemical compound
NITD008
|
|
Trade names | NITD008 |
---|
|
(2R,3R,4R,5R)-2-(4-Amino-7H-pyrrolo[2,3-d]pyrimidin-7-yl)-3-ethynyl-5-(hydroxymethyl)tetrahydrofuran-3,4-diol
|
CAS Number | |
---|
PubChem
CID | |
---|
ChemSpider | |
---|
UNII | |
---|
ChEMBL | |
---|
|
Formula | C13H14N4O4 |
---|
Molar mass | 290.279 g·mol−1 |
---|
3D model (
JSmol) | |
---|
C#C[C@]1([C@@H]([C@H](O[C@H]1N2C=CC3=C2N=CN=C3N)CO)O)O
|
InChI=1S/C13H14N4O4/c1-2-13(20)9(19)8(5-18)21-12(13)17-4-3-7-10(14)15-6-16-11(7)17/h1,3-4,6,8-9,12,18-20H,5H2,(H2,14,15,16)/t8-,9-,12-,13-/m1/s1 Key:NKRAIOQPSBRMOV-NRMKKVEVSA-N
|
NITD008 is an
antiviral drug classified as an
adenosine analog (a type of
nucleoside analog). It was developed as a potential treatment for
flavivirus infections and shows broad spectrum antiviral activity against many related viruses such as
dengue virus,
West Nile virus,
yellow fever virus,
Powassan virus,
hepatitis C virus,
Kyasanur Forest disease virus,
Omsk hemorrhagic fever virus, and
Zika virus.
[1]
[2]
[3] However, NITD008 proved too toxic in pre-clinical animal testing to be suitable for human trials, but it continues to be used in research to find improved treatments for emerging viral diseases.
[4]
See also
-
Favipiravir, a drug approved by China, Germany, Indonesia, Iran, Japan, Thailand, and Turkey for treating COVID-19 patients
-
MK-608, a drug with a similar structure
-
Remdesivir , FDA approved antiviral drug with a similar structure
-
Ribavirin, another antiviral drug with teratogenic side effects that was patented by Merck in 1971 and approved by the FDA in 1986
References
-
^ Yin Z, Chen YL, Schul W, Wang QY, Gu F, Duraiswamy J, et al. (December 2009).
"An adenosine nucleoside inhibitor of dengue virus". Proceedings of the National Academy of Sciences of the United States of America. 106 (48): 20435–9.
Bibcode:
2009PNAS..10620435Y.
doi:
10.1073/pnas.0907010106.
PMC
2787148.
PMID
19918064.
-
^ Lo MK, Shi PY, Chen YL, Flint M, Spiropoulou CF (June 2016).
"In vitro antiviral activity of adenosine analog NITD008 against tick-borne flaviviruses". Antiviral Research. 130: 46–9.
doi:
10.1016/j.antiviral.2016.03.013.
PMC
5096641.
PMID
27016316.
-
^ Deng YQ, Zhang NN, Li CF, Tian M, Hao JN, Xie XP, et al. (October 2016).
"Adenosine Analog NITD008 Is a Potent Inhibitor of Zika Virus". Open Forum Infectious Diseases. 3 (4): ofw175.
doi:
10.1093/ofid/ofw175.
PMC
5063548.
PMID
27747251.
-
^ Nelson J, Roe K, Orillo B, Shi PY, Verma S (October 2015).
"Combined treatment of adenosine nucleoside inhibitor NITD008 and histone deacetylase inhibitor vorinostat represents an immunotherapy strategy to ameliorate West Nile virus infection". Antiviral Research. 122: 39–45.
doi:
10.1016/j.antiviral.2015.07.008.
PMC
4853296.
PMID
26225754.